Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort

被引:17
作者
Assuncao, Helena [1 ]
Jesus, Diogo [2 ,3 ]
Larosa, Maddalena [4 ]
Henriques, Carla [5 ,6 ]
Matos, Ana [5 ,7 ]
Le Guern, Veronique [8 ,9 ]
Rubino, Francisco [10 ]
da Silva, Jose A. P. [1 ,11 ]
Rua-Figueroa, Inigo [10 ]
Costedoat-Chalumeau, Nathalie [8 ,9 ]
Doria, Andrea [4 ]
Ines, Luis S. [1 ,3 ]
机构
[1] Ctr Hosp & Univ Coimbra, Rheumatol Dept, Coimbra, Portugal
[2] Ctr Hosp Leiria, Rheumatol Dept, Leiria, Portugal
[3] Univ Beira Interior, Fac Hlth Sci, Covilha, Portugal
[4] Univ Padua, Div Rheumatol, Padua, Italy
[5] Polytech Inst Viseu, Sch Technol & Management, Viseu, Portugal
[6] Univ Coimbra, Ctr Math, Coimbra, Portugal
[7] Polytech Viseu, CISeD Res Ctr Digital Serv, Viseu, Portugal
[8] Cochin Hosp, AP HP, Internal Med Dept, Paris, France
[9] Univ Paris, Paris, France
[10] Doctor Negrin Univ Hosp, Rheumatol Dept, Las Palmas Gran Canaria, Spain
[11] Univ Coimbra, Fac Med, Coimbra, Portugal
关键词
systemic lupus erythematosus; treat-to-target; SLE-DAS; LLDAS; SYSTEMIC-LUPUS-ERYTHEMATOSUS; TREAT-TO-TARGET; REMISSION; DAMAGE; RECOMMENDATIONS; ATTAINMENT; LLDAS;
D O I
10.1093/rheumatology/keab895
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To derive and validate a definition of low disease activity (LDA) for SLE based on the SLE Disease Activity Score (SLE-DAS), in a real-life multicentre cohort of SLE patients. Methods. Derivation was conducted using data from a monocentric cohort of SLE (Portugal), and validation was performed in a multicentre cohort (Italy, France and Spain). The Lupus Low Disease Activity State (LLDAS) was used as comparator. We applied receiver operating characteristics curve analysis against the LLDAS to determine the cut-off of SLE-DAS for LDA using bootstrap methodology. In a second step, we tested a definition of SLE-DAS LDA that included: (i) the statistically derived SLE-DAS upper threshold for LDA and (ii) prednisone dose <= 7.5 mg/day. In the multicentre validation cohort, we assessed the classification performance of this SLE-DAS LDA definition. Results. We included 774 patients, 300 in the derivation and 474 in the validation cohort. In the derivation cohort, the optimal cut-off to identify patients in LLDAS was SLE-DAS <= 2.48, presenting an area under the curve of 0.965 (95% CI 0.935, 0.994). When applied to the multicentre validation cohort, the SLE-DAS LDA definition showed a sensitivity of 97.1% and a specificity of 97.7% for LLDAS and an almost perfect agreement (Cohen's Kappa =0.933; P < 0.001). McNemar's test found no significant differences between the two definitions (P = 0 .092). Conclusion. The SLE-DAS LDA is a validated, accurate and easy-to-use definition for classifying SLE patients in LDA state.
引用
收藏
页码:3309 / 3316
页数:8
相关论文
共 42 条
  • [21] Performance of SLEDAI-2K to detect a clinically meaningful change in SLE disease activity: a 36-month prospective cohort study of 334 patients
    Jesus, D.
    Rodrigues, M.
    Matos, A.
    Henriques, C.
    Pereira da Silva, J. A.
    Ines, L. S.
    [J]. LUPUS, 2019, 28 (05) : 607 - 612
  • [22] Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity
    Jesus, Diogo
    Larosa, Maddalena
    Henriques, Carla
    Matos, Ana
    Zen, Margherita
    Tome, Paulo
    Alves, Valter
    Costa, Nuno
    Le Guern, Veronique
    Iaccarino, Luca
    Costedoat-Chalumeau, Nathalie
    Doria, Andrea
    Ines, Luis Sousa
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (12) : 1568 - 1574
  • [23] Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity
    Jesus, Diogo
    Matos, Ana
    Henriques, Carla
    Zen, Margherita
    Larosa, Maddalena
    Iaccarino, Luca
    Pereira Da Silva, Jose Antonio
    Doria, Andrea
    Ines, Luis Sousa
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (03) : 365 - 371
  • [24] MEASUREMENT OF OBSERVER AGREEMENT FOR CATEGORICAL DATA
    LANDIS, JR
    KOCH, GG
    [J]. BIOMETRICS, 1977, 33 (01) : 159 - 174
  • [25] The impact of class imbalance in classification performance metrics based on the binary confusion matrix
    Luque, Amalia
    Carrasco, Alejandro
    Martin, Alejandro
    de las Heras, Ana
    [J]. PATTERN RECOGNITION, 2019, 91 : 216 - 231
  • [26] Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus
    Mok, Chi Chiu
    Ho, Ling Yin
    Tse, Sau Mei
    Chan, Kar Li
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 (08) : 1420 - 1425
  • [27] Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study
    Morand, Eric F.
    Isenberg, David A.
    Wallace, Daniel J.
    Kao, Amy H.
    Vazquez-Mateo, Cristina
    Chang, Peter
    Pudota, Kishore
    Aranow, Cynthia
    Merrill, Joan T.
    [J]. RHEUMATOLOGY, 2020, 59 (10) : 2930 - 2938
  • [28] Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
    Morand, Eric F.
    Trasieva, Teodora
    Berglind, Anna
    Illei, Gabor G.
    Tummala, Raj
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (05) : 706 - 713
  • [29] Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosus
    Oon, Shereen
    Huq, Molla
    Golder, Vera
    Ong, Pei Xuan
    Morand, Eric F.
    Nikpour, Mandana
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 (05) : 629 - 633
  • [30] How to use the Lupus Low Disease Activity State (LLDAS) in clinical trials
    Parodis, Ioannis
    Nikpour, Mandana
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 (07)